Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to $541000.0.

  • Abeona Therapeutics' Other Non-Current Assets rose 6005.92% to $541000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $541000.0, marking a year-over-year increase of 6005.92%. This contributed to the annual value of $338000.0 for FY2024, which is 0.0% changed from last year.
  • As of Q3 2025, Abeona Therapeutics' Other Non-Current Assets stood at $541000.0, which was up 6005.92% from $338000.0 recorded in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' Other Non-Current Assets registered a high of $5.9 million during Q4 2021, and its lowest value of $338000.0 during Q4 2022.
  • Its 5-year average for Other Non-Current Assets is $1.6 million, with a median of $338000.0 in 2022.
  • The largest annual percentage gain for Abeona Therapeutics' Other Non-Current Assets in the last 5 years was 50420.51% (2022), contrasted with its biggest fall of 9426.24% (2022).
  • Over the past 5 years, Abeona Therapeutics' Other Non-Current Assets (Quarter) stood at $5.9 million in 2021, then tumbled by 94.26% to $338000.0 in 2022, then changed by 0.0% to $338000.0 in 2023, then changed by 0.0% to $338000.0 in 2024, then skyrocketed by 60.06% to $541000.0 in 2025.
  • Its last three reported values are $541000.0 in Q3 2025, $338000.0 for Q2 2025, and $338000.0 during Q1 2025.